Andrew Michael Waters , PhD

KRAS is the most frequently mutated oncogene in human cancer and is mutated with near universal frequency in pancreatic cancer. Using cutting-edge techniques and first-in-class KRAS inhibitors that target KRAS mutations frequently found in PDAC, the Waters lab focuses on identifying the undiscovered molecular mechanisms by which KRAS-mutant pancreatic cancer cells adapt to KRAS inhibitor treatment. A major goal of the lab is to identify therapeutic vulnerabilities and KRAS inhibitor combination strategies that will extend the effectiveness of KRAS inhibitors for patients with pancreatic cancer.

PhD: The Catholic University of America Washington, DC, (Cellular and Microbial Biology)

MS: Johns Hopkins University Baltimore, MD, (Biotechnology)

BS: James Madison University Harrisonburg, VA, (Integrated Science and Technology: Biotechnology)

KRAS-mutant cancers
MYC
Pancreatic Cancer
Lung Cancer
Colorectal Cancer

- Research Associate, RAS Initiative, NCI Frederick National Lab for Cancer Reseach, Frederick, MD

Investigators:Andrew Waters 2018 -2021 American Cancer Society Defining the Molecular Basis of KRAS Addiction in Pancreatic Cancer Role:PI 163,500 Completed Type:Fellowship

Grant: #K22CA276632 Investigators:Waters, Andrew 01-01-2023 -12-31-2025 National Cancer Institute Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer Role:PI 191864.29 Hold Level:Federal

Grant: #Steven Goldman Memorial Pancreatic Cancer Research Fund Investigators:Andrew Waters 11-15-2023 -11-14-2024 University of Cincinnati Cancer Center Evaluation of molecular consequences and resistance mechanisms to KRAS Q61H in PDAC Role:PI 50,000 Active Type:Grant

Peer Reviewed Publications

Huynh, Minh V; Hobbs, G Aaron; Schaefer, Antje; Pierobon, Mariaelena; Carey, Leiah M; Diehl, J Nathaniel; DeLiberty, Jonathan M; Thurman, Ryan D; Cooke, Adelaide R; Goodwin, Craig M; Cook, Joshua H; Lin, Lin; Waters, Andrew M; Rashid, Naim U; Petricoin, Emanuel F; Campbell, Sharon L; Haigis, Kevin M; Simeone, Diane M; Lyssiotis, Costas A; Cox, Adrienne D; Der, Channing J (2022. ) Functional and biological heterogeneity of KRASQ61 mutations.Science signaling, , 15 (746 ) ,eabn2694 More Information

Javaid, Sehrish; Schaefer, Antje; Goodwin, Craig M; Nguyen, Victoria V; Massey, Frances L; Pierobon, Mariaelena; Gambrell-Sanders, Da'Jhnae; Waters, Andrew M; Lambert, Kathryn N; Diehl, J Nathaniel; Hobbs, G Aaron; Wood, Kris C; Petricoin, Emanuel F; Der, Channing J; Cox, Adrienne D (2022. ) Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.Molecular cancer therapeutics, , 21 (5 ) ,762-774 More Information

Cook, Danielle R; Kang, Melissa; Martin, Timothy D; Galanko, Joseph A; Loeza, Gabriela H; Trembath, Dimitri G; Justilien, Verline; Pickering, Karen A; Vincent, David F; Jarosch, Armin; Jurmeister, Philipp; Waters, Andrew M; Hibshman, Priya S; Campbell, Andrew D; Ford, Catriona A; Keku, Temitope O; Yeh, Jen Jen; Lee, Michael S; Cox, Adrienne D; Fields, Alan P; Sandler, Robert S; Sansom, Owen J; Sers, Christine; Schaefer, Antje; Der, Channing J (2022. ) Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth.Cancer research, , 82 (1 ) ,90-104 More Information

Klomp, Jennifer E; Lee, Ye S; Goodwin, Craig M; Papke, Björn; Klomp, Jeff A; Waters, Andrew M; Stalnecker, Clint A; DeLiberty, Jonathan M; Drizyte-Miller, Kristina; Yang, Runying; Diehl, J Nathaniel; Yin, Hongwei H; Pierobon, Mariaelena; Baldelli, Elisa; Ryan, Meagan B; Li, Siqi; Peterson, Jackson; Smith, Amber R; Neal, James T; McCormick, Aaron K; Kuo, Calvin J; Counter, Christopher M; Petricoin, Emanuel F; Cox, Adrienne D; Bryant, Kirsten L; Der, Channing J (2021. ) CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.Cell reports, , 37 (9 ) ,110060 More Information

Waters, Andrew M; Khatib, Tala O; Papke, Bjoern; Goodwin, Craig M; Hobbs, G Aaron; Diehl, J Nathaniel; Yang, Runying; Edwards, A Cole; Walsh, Katherine H; Sulahian, Rita; McFarland, James M; Kapner, Kevin S; Gilbert, Thomas S K; Stalnecker, Clint A; Javaid, Sehrish; Barkovskaya, Anna; Grover, Kajal R; Hibshman, Priya S; Blake, Devon R; Schaefer, Antje; Nowak, Katherine M; Klomp, Jennifer E; Hayes, Tikvah K; Kassner, Michelle; Tang, Nanyun; Tanaseichuk, Olga; Chen, Kaisheng; Zhou, Yingyao; Kalkat, Manpreet; Herring, Laura E; Graves, Lee M; Penn, Linda Z; Yin, Hongwei H; Aguirre, Andrew J; Hahn, William C; Cox, Adrienne D; Der, Channing J (2021. ) Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.Cell reports, , 35 (13 ) ,109291 More Information

Waters, Andrew M; Der, Channing J (2021. ) Validation of Isoform- and Mutation-Specific RAS Antibodies.Methods in molecular biology (Clifton, N.J.), , 2262 ,91-103 More Information

Ozkan-Dagliyan, Irem; Diehl, J Nathaniel; George, Samuel D; Schaefer, Antje; Papke, Bjoern; Klotz-Noack, Kathleen; Waters, Andrew M; Goodwin, Craig M; Gautam, Prson; Pierobon, Mariaelena; Peng, Sen; Gilbert, Thomas S K; Lin, Kevin H; Dagliyan, Onur; Wennerberg, Krister; Petricoin, Emanuel F; Tran, Nhan L; Bhagwat, Shripad V; Tiu, Ramon V; Peng, Sheng-Bin; Herring, Laura E; Graves, Lee M; Sers, Christine; Wood, Kris C; Cox, Adrienne D; Der, Channing J (2020. ) Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Cell reports, , 31 (11 ) ,107764 More Information

Hobbs, G Aaron; Baker, Nicole M; Miermont, Anne M; Thurman, Ryan D; Pierobon, Mariaelena; Tran, Timothy H; Anderson, Andrew O; Waters, Andrew M; Diehl, J Nathaniel; Papke, Bjoern; Hodge, Richard G; Klomp, Jennifer E; Goodwin, Craig M; DeLiberty, Jonathan M; Wang, Junning; Ng, Raymond W S; Gautam, Prson; Bryant, Kirsten L; Esposito, Dominic; Campbell, Sharon L; Petricoin, Emanuel F; Simanshu, Dhirendra K; Aguirre, Andrew J; Wolpin, Brian M; Wennerberg, Krister; Rudloff, Udo; Cox, Adrienne D; Der, Channing J (2020. ) Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.Cancer discovery, , 10 (1 ) ,104-123 More Information

Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J (2019. ) Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.Nature medicine, , 25 (4 ) ,628-640 More Information

Waters, Andrew M; Der, Channing J (2018. ) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Cold Spring Harbor perspectives in medicine, , 8 (9 ) , More Information

Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel; Yi, Ming; Afghani, Shervin; Burgan, William; Fer, Nicole; Strathern, Leslie A; Powell, Katie; Smith, Brian; Waters, Andrew M; Drubin, David; Thomson, Ty; Liao, Rosy; Greninger, Patricia; Stein, Giovanna T; Murchie, Ellen; Cortez, Eliane; Egan, Regina K; Procter, Lauren; Bess, Matthew; Cheng, Kwong Tai; Lee, Chih-Shia; Lee, Liam Changwoo; Fellmann, Christof; Stephens, Robert; Luo, Ji; Lowe, Scott W; Benes, Cyril H; McCormick, Frank (2018. ) Differential Effector Engagement by Oncogenic KRAS.Cell reports, , 22 (7 ) ,1889-1902 More Information

Waters, Andrew M; Ozkan-Dagliyan, Irem; Vaseva, Angelina V; Fer, Nicole; Strathern, Leslie A; Hobbs, G Aaron; Tessier-Cloutier, Basile; Gillette, William K; Bagni, Rachel; Whiteley, Gordon R; Hartley, James L; McCormick, Frank; Cox, Adrienne D; Houghton, Peter J; Huntsman, David G; Philips, Mark R; Der, Channing J (2017. ) Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.Science signaling, , 10 (498 ) , More Information

Ye, Xiaoying; Chan, King C; Waters, Andrew M; Bess, Matthew; Harned, Adam; Wei, Bih-Rong; Loncarek, Jadranka; Luke, Brian T; Orsburn, Benjamin C; Hollinger, Bradley D; Stephens, Robert M; Bagni, Rachel; Martinko, Alex; Wells, James A; Nissley, Dwight V; McCormick, Frank; Whiteley, Gordon; Blonder, Josip (2016. ) Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface.Oncotarget, , 7 (52 ) ,86948-86971 More Information

Waters, Andrew M; Bagni, Rachel; Portugal, Franklin; Hartley, James L Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells.PloS one, , 11 (9 ) ,e0163272 More Information

Goodwin, Craig M; Waters, Andrew M; Klomp, Jennifer E; Javaid, Sehrish; Bryant, Kirsten L; Stalnecker, Clint A; Drizyte-Miller, Kristina; Papke, Bjoern; Yang, Runying; Amparo, Amber M; Ozkan-Dagliyan, Irem; Baldelli, Elisa; Calvert, Valerie; Pierobon, Mariaelena; Sorrentino, Jessica A; Beelen, Andrew P; Bublitz, Natalie; Lüthen, Mareen; Wood, Kris C; Petricoin, Emanuel F; Sers, Christine; McRee, Autumn J; Cox, Adrienne D; Der, Channing J (2023. ) Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.Cancer research, , 83 (1 ) ,141-157 More Information

Edwards, A Cole; Stalnecker, Clint A; Jean Morales, Alexis; Taylor, Khalilah E; Klomp, Jennifer E; Klomp, Jeffrey A; Waters, Andrew M; Sudhakar, Niranjan; Hallin, Jill; Tang, Tracy T; Olson, Peter; Post, Leonard; Christensen, James G; Cox, Adrienne D; Der, Channing J (2023. ) TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors.Cancer research, , More Information

Bryant, Kirsten L; Stalnecker, Clint A; Zeitouni, Daniel; Klomp, Jennifer E; Peng, Sen; Tikunov, Andrey P; Gunda, Venugopal; Pierobon, Mariaelena; Waters, Andrew M; George, Samuel D; Tomar, Garima; Papke, Björn; Hobbs, G Aaron; Yan, Liang; Hayes, Tikvah K; Diehl, J Nathaniel; Goode, Gennifer D; Chaika, Nina V; Wang, Yingxue; Zhang, Guo-Fang; Witkiewicz, Agnieszka K; Knudsen, Erik S; Petricoin, Emanuel F; Singh, Pankaj K; Macdonald, Jeffrey M; Tran, Nhan L; Lyssiotis, Costas A; Ying, Haoqiang; Kimmelman, Alec C; Cox, Adrienne D; Der, Channing J (2020. ) Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.Nature medicine, , 26 (6 ) ,982 More Information

Long, Szu-Aun; Amparo, Amber M; Goodhart, Grace; Ahmad, Syed A; Waters, Andrew M (2024. ) Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment.Frontiers in oncology, , 14 ,1402128 More Information

Nussbaum, Daniel P; Martz, Colin A; Waters, Andrew M; Barrera, Alejandro; Liu, Annie; Rutter, Justine C; Cerda-Smith, Christian G; Stewart, Amy E; Wu, Chao; Cakir, Merve; Levandowski, Cecilia B; Kantrowitz, David E; McCall, Shannon J; Pierobon, Mariaelena; Petricoin, Emanuel F; Joshua Smith, J; Reddy, Timothy E; Der, Channing J; Taatjes, Dylan J; Wood, Kris C (2024. ) Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.NPJ precision oncology, , 8 (1 ) ,124 More Information

Holderfield, Matthew; Lee, Bianca J; Jiang, Jingjing; Tomlinson, Aidan; Seamon, Kyle J; Mira, Alessia; Patrucco, Enrico; Goodhart, Grace; Dilly, Julien; Gindin, Yevgeniy; Dinglasan, Nuntana; Wang, Yingyun; Lai, Lick Pui; Cai, Shurui; Jiang, Lingyan; Nasholm, Nicole; Shifrin, Nataliya; Blaj, Cristina; Shah, Harshit; Evans, James W; Montazer, Nilufar; Lai, Oliver; Shi, Jade; Ahler, Ethan; Quintana, Elsa; Chang, Stephanie; Salvador, Anthony; Marquez, Abby; Cregg, Jim; Liu, Yang; Milin, Anthony; Chen, Anqi; Ziv, Tamar Bar; Parsons, Dylan; Knox, John E; Klomp, Jennifer E; Roth, Jennifer; Rees, Matthew; Ronan, Melissa; Cuevas-Navarro, Antonio; Hu, Feng; Lito, Piro; Santamaria, David; Aguirre, Andrew J; Waters, Andrew M; Der, Channing J; Ambrogio, Chiara; Wang, Zhengping; Gill, Adrian L; Koltun, Elena S; Smith, Jacqueline A M; Wildes, David; Singh, Mallika (2024. ) Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Nature, , More Information

Postdoctoral Fellowship, Laboratory of Channing Der, University of North Carolina at Chapel Hill, , Chapel Hill NC

Academic - Vontz Center
Rm. 2124
Cincinnati  Ohio, 45267-0521
andrew.waters@uc.edu